Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

Clinical trial NCT05952024 · RECRUITING

Trial details

NCT number: NCT05952024
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Diffuse Large B-Cell Lymphoma

Start date: 2024-07-16
Primary completion: 2029-04-22
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.